GleamWall
中文EN

ADXN Addex Therapeutics Ltd. IFRS

Pharmaceutical Preparations · Nasdaq · SEC CIK 1574232 · Reporting currency CHF · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY-74.9%
TTM net income YoY166.8%
TTM EPS YoY150.0%
Revenue 3-yr CAGR-48.3%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-681.8%
Net margin1,746.0%
FCF margin-1,330.1%
EBITDA margin—

Returns

ROE130.4%
ROA92.1%
ROIC (approx.)-120.4%
Asset turnover0.05x

Leverage & solvency

Liabilities / assets9.4%
Debt / equity0.00x
Current ratio4.42x
Interest coverage-1,712.39x

Cash quality & payout

Operating cash flow / net income-0.76x
Accruals ratio162.3%
Payout ratio—
Capex / revenue0.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Unit: CHF FY2024*2024-12-31FY2023*2023-12-31
Income statement
Revenue404,1021.61M
R&D expense854,3051.19M
SG&A expense2.31M2.67M
Operating income-2.76M-2.24M
Interest expense1,6091,644
Pretax income-4.91M-2.50M
Income tax00
Net income7.06M-10.56M
EPS (basic)0.07-0.14
EPS (diluted)0.07-0.14
Balance sheet
Cash & equivalents3.34M3.87M
Receivables15,513110,361
Current assets3.54M4.23M
PP&E, netmay include right-of-use assets (IFRS)1,13122,604
Total assets10.68M4.64M
Current liabilities802,0932.89M
Short-term debt00
Long-term debt00
Total debt00
Total liabilities1.00M3.50M
Shareholders' equity9.68M1.15M
Net debt-3.34M-3.87M
Shares outstanding128.29M125.20M
Cash flow statement
Operating cash flow-5.37M-7.99M
Capital expenditure1,2736,842
Free cash flow-5.37M-8.00M
Investing cash flow4.65M-6,842
Financing cash flow104,9185.26M
Stock-based compensation502,9641.79M

Free plan shows the latest 2 periods; Pro shows all 8 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company does not report gross profit in XBRL.

· Amounts are in the company's reporting currency, CHF, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.